We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Synlogic's (SYBX) Begins Phase I Study for PKU Treatment
Read MoreHide Full Article
Synlogic (SYBX - Free Report) announced that it has initiated the phase I study of SYNB1934, an investigational synthetic biotic candidate for the treatment of phenylketonuria (“PKU”). The candidate will be administered orally, and is being developed for all age groups as well as genotypes.
SYNB1934 is an evolved strain of SYNB1618, which is currently in phase II study. The data from this study is anticipated in second-half 2021.
PKU is marked by an inability to break down phenylalanine (“Phe”), an amino acid found in many foods. High Phe levels can result in serious neurological and neuropsychological problems affecting a person’s actions. Both SYNB1618 and SYNB1934 are being evaluated to lower Phe levels through the consumption of Phe in the gastrointestinal tract, and enable consumption of more natural dietary protein.
We note that while both the candidates offer the same potential treatment, data from preclinical in vivo and in vitro studies indicates that the evolved strain has demonstrated greater than two-fold improvement in breaking down Phe levels based on the production of Phe metabolites.
Shares of Synlogic have rallied 60.2% so far this year against the industry’s 4.1% decline.
Image Source: Zacks Investment Research
The phase I multiple ascending dose study of SYNB1934 will evaluate the drug’s Phe consumption activity and head-to-head comparison with SNYB1618 in healthy volunteers using biomarkers of Phe consumption. Synlogic plans to use the data from the ongoing studies to select either one of the candidates for late-stage development.
Since PKU is an inherited metabolic disease that manifests at birth, many countries screen their infants at birth for an early diagnosis and treatment to avoid intellectual disability as well as other complications. A success in the development of the synthetic biotic candidates will boost the company’s prospects.
Image: Bigstock
Synlogic's (SYBX) Begins Phase I Study for PKU Treatment
Synlogic (SYBX - Free Report) announced that it has initiated the phase I study of SYNB1934, an investigational synthetic biotic candidate for the treatment of phenylketonuria (“PKU”). The candidate will be administered orally, and is being developed for all age groups as well as genotypes.
SYNB1934 is an evolved strain of SYNB1618, which is currently in phase II study. The data from this study is anticipated in second-half 2021.
PKU is marked by an inability to break down phenylalanine (“Phe”), an amino acid found in many foods. High Phe levels can result in serious neurological and neuropsychological problems affecting a person’s actions. Both SYNB1618 and SYNB1934 are being evaluated to lower Phe levels through the consumption of Phe in the gastrointestinal tract, and enable consumption of more natural dietary protein.
We note that while both the candidates offer the same potential treatment, data from preclinical in vivo and in vitro studies indicates that the evolved strain has demonstrated greater than two-fold improvement in breaking down Phe levels based on the production of Phe metabolites.
Shares of Synlogic have rallied 60.2% so far this year against the industry’s 4.1% decline.
Image Source: Zacks Investment Research
The phase I multiple ascending dose study of SYNB1934 will evaluate the drug’s Phe consumption activity and head-to-head comparison with SNYB1618 in healthy volunteers using biomarkers of Phe consumption. Synlogic plans to use the data from the ongoing studies to select either one of the candidates for late-stage development.
Since PKU is an inherited metabolic disease that manifests at birth, many countries screen their infants at birth for an early diagnosis and treatment to avoid intellectual disability as well as other complications. A success in the development of the synthetic biotic candidates will boost the company’s prospects.
Zacks Rank & Other Stocks to Consider
Synlogic currently carries a Zacks Rank #2 (Buy).
Other favorable stocks in the healthcare sector include Acadia Pharmaceuticals (ACAD - Free Report) , Biomarin Pharmaceutical (BMRN - Free Report) and Exact Sciences (EXAS - Free Report) . While Biomarin and Exact Sciences currently carry a Zacks Rank #1 (Strong Buy), Acadia holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Acadia’s loss estimates for 2022 have narrowed from $0.83 to $0.81 per share in the past 30 days.
Biomarin’s earnings estimates for 2022 have increased from $2.33 to $2.35 per share in the past 30 days.
Exact Sciences’ loss estimates for 2021 have narrowed from $2.65 to $2.51 per share in the past 30 days.
Synlogic, Inc. Price
Synlogic, Inc. price | Synlogic, Inc. Quote